HK1086573A1 - Quinazoline derivatives for treatment of cancer - Google Patents

Quinazoline derivatives for treatment of cancer

Info

Publication number
HK1086573A1
HK1086573A1 HK06106582A HK06106582A HK1086573A1 HK 1086573 A1 HK1086573 A1 HK 1086573A1 HK 06106582 A HK06106582 A HK 06106582A HK 06106582 A HK06106582 A HK 06106582A HK 1086573 A1 HK1086573 A1 HK 1086573A1
Authority
HK
Hong Kong
Prior art keywords
cancer
treatment
quinazoline derivatives
quinazoline
derivatives
Prior art date
Application number
HK06106582A
Other languages
English (en)
Inventor
Heron Nicola Murdoch
Pasquet Georges Rene
Mortlock Andrew Austen
Jung Frederic Henri
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1086573A1 publication Critical patent/HK1086573A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK06106582A 2003-04-16 2006-06-08 Quinazoline derivatives for treatment of cancer HK1086573A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290951 2003-04-16
PCT/GB2004/001614 WO2004094410A1 (en) 2003-04-16 2004-04-14 Chemical compounds

Publications (1)

Publication Number Publication Date
HK1086573A1 true HK1086573A1 (en) 2006-09-22

Family

ID=33305809

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06106582A HK1086573A1 (en) 2003-04-16 2006-06-08 Quinazoline derivatives for treatment of cancer

Country Status (23)

Country Link
US (1) US7691867B2 (es)
EP (1) EP1613619B1 (es)
JP (1) JP4709139B2 (es)
KR (1) KR20060003351A (es)
CN (1) CN1809557B (es)
AR (1) AR043875A1 (es)
AT (1) ATE390422T1 (es)
AU (1) AU2004232527A1 (es)
BR (1) BRPI0409427A (es)
CA (1) CA2522079A1 (es)
CL (1) CL2004000797A1 (es)
CO (1) CO5640037A2 (es)
DE (1) DE602004012725T2 (es)
ES (1) ES2301981T3 (es)
HK (1) HK1086573A1 (es)
IS (1) IS8125A (es)
MX (1) MXPA05011076A (es)
NO (1) NO20054842L (es)
RU (1) RU2005135337A (es)
TW (1) TW200510392A (es)
UY (1) UY28271A1 (es)
WO (1) WO2004094410A1 (es)
ZA (1) ZA200508372B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL211694B1 (pl) * 2001-12-24 2012-06-29 Astrazeneca Ab Podstawiona pochodna chinazoliny, jej zastosowania oraz jej kompozycja farmaceutyczna
MY136174A (en) * 2002-12-24 2008-08-29 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
EP1635837B1 (en) * 2003-06-02 2008-07-16 AstraZeneca AB (3-((quinazolin-4-yl)amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
ME01267B (me) 2004-05-06 2013-06-20 Warner Lambert Co 4-fenilaminokinazolin-6-ilamidi
US20090036474A1 (en) * 2004-10-12 2009-02-05 Patrick Ple Quinazoline derivatives for use against cancer
WO2006040522A1 (en) * 2004-10-12 2006-04-20 Astrazeneca Ab Quinoline derivatives
MX2007004403A (es) 2004-10-12 2007-04-27 Astrazeneca Ab Derivados de quinazolina.
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP6097946B2 (ja) * 2004-11-17 2017-03-22 レクサン ファーマシューティカルズ インコーポレイテッド １−［（６，７−置換−アルコキシキノキサリニル）アミノカルボニル］−４−（ヘテロ）アリールピペラジン誘導体
GB0510963D0 (en) * 2005-05-28 2005-07-06 Astrazeneca Ab Chemical compounds
JP2008542345A (ja) * 2005-05-28 2008-11-27 アストラゼネカ アクチボラグ キナゾリン類及びオーロラキナーゼ阻害剤としてのその使用
US20080269500A1 (en) * 2005-09-22 2008-10-30 Astrazeneca Ab Process for the Preparation of 4-Aminopyrazole Derivatives
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0601215D0 (en) * 2006-01-21 2006-03-01 Astrazeneca Ab Chemical compounds
EP1994023A1 (en) * 2006-03-02 2008-11-26 AstraZeneca AB Quinazoline derivatives
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2007113565A1 (en) * 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives as anti-cancer agents
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
FR2908409B1 (fr) 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
TWI577671B (zh) * 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
CN104098551B (zh) * 2013-04-03 2019-03-22 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代喹唑啉类衍生物
CN103382158B (zh) * 2013-07-29 2015-11-18 张家港市大伟助剂有限公司 一种2-环戊基氨基乙醇的制备方法
JP6567505B2 (ja) * 2013-09-19 2019-08-28 ピエール、ファーブル、メディカマン キナゾリン誘導体およびｄｎａメチルトランスフェラーゼ阻害剤としてのその使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
TW321649B (es) * 1994-11-12 1997-12-01 Zeneca Ltd
WO1997017329A1 (fr) * 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Derives de quinoline et derives de quinazoline inhibant l'autophosphorylation d'un recepteur de facteur de croissance originaire de plaquettes, et compositions pharmaceutiques les contenant
WO2001021596A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
NZ522696A (en) * 2000-06-28 2004-08-27 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
PL211694B1 (pl) 2001-12-24 2012-06-29 Astrazeneca Ab Podstawiona pochodna chinazoliny, jej zastosowania oraz jej kompozycja farmaceutyczna
WO2004018430A1 (ja) * 2002-08-23 2004-03-04 Kirin Beer Kabushiki Kaisha ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
AU2003294142A1 (en) 2002-12-24 2004-07-22 Astrazeneca Ab Therapeutic quinazoline derivatives
MY136174A (en) 2002-12-24 2008-08-29 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
WO2004058752A1 (en) 2002-12-24 2004-07-15 Astrazeneca Ab Quinazoline compounds
EP1635837B1 (en) * 2003-06-02 2008-07-16 AstraZeneca AB (3-((quinazolin-4-yl)amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
ES2301981T3 (es) 2008-07-01
CA2522079A1 (en) 2004-11-04
EP1613619B1 (en) 2008-03-26
WO2004094410A1 (en) 2004-11-04
DE602004012725D1 (de) 2008-05-08
AU2004232527A1 (en) 2004-11-04
NO20054842L (no) 2005-11-08
MXPA05011076A (es) 2006-01-24
DE602004012725T2 (de) 2009-04-16
TW200510392A (en) 2005-03-16
KR20060003351A (ko) 2006-01-10
CO5640037A2 (es) 2006-05-31
ATE390422T1 (de) 2008-04-15
EP1613619A1 (en) 2006-01-11
ZA200508372B (en) 2007-04-25
BRPI0409427A (pt) 2006-04-18
CL2004000797A1 (es) 2005-05-27
RU2005135337A (ru) 2006-06-10
US7691867B2 (en) 2010-04-06
AR043875A1 (es) 2005-08-17
JP4709139B2 (ja) 2011-06-22
IS8125A (is) 2005-11-11
JP2006523660A (ja) 2006-10-19
CN1809557B (zh) 2012-07-04
CN1809557A (zh) 2006-07-26
UY28271A1 (es) 2004-11-30
US20060270692A1 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
HK1086573A1 (en) Quinazoline derivatives for treatment of cancer
HK1204476A1 (en) Compounds and methods for treatment of cancer
EP1667680A4 (en) COMBINED METHODS OF TREATING CANCER
EP1613308A4 (en) CANCER TREATMENT METHODS
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
EP1663259A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
SI1948180T1 (sl) Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
IL164599A0 (en) Combination therapy for the treatment of cancer
IL175911A0 (en) Analoges of benzoquinone-containing ansamycins for the treatment of cancer
HK1164767A1 (en) Compounds and methods for the treatment of cancer
IL177455A0 (en) Pyrazoline derivatives useful for the treatment of cancer
IL175689A0 (en) Enoxaparin for the treatment of cancer
EP1677805A4 (en) TREATMENT OF PANCREATIC CANCER
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003231803A8 (en) Treatment of cancer with mefloquire
GB0329416D0 (en) Treatment of cancer
DE60328516D1 (de) Thia-epothilon derivate zur krebsbehandlung
PL1680405T3 (pl) Pochodne bengamidu i ich zastosowanie do leczenia chorób nowotworowych
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
GB0410379D0 (en) Treatment of cancer
GB0423273D0 (en) Treatment of cancer
EP1616190A4 (en) DIAGNOSIS OF CANCER AT AN ADVANCED STAGE
GB0327667D0 (en) Treatment of cancer
AU2003217925A1 (en) Treatment of metastatic institute for cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130414